24/7 Market News Snapshot 29 January, 2025 – Silexion Therapeutics Corp Ordinary Shares (NASDAQ:SLXN)

January 29, 2025

DENVER, Colo., 29 January, 2025 (247marketnews.com) – (NASDAQ:SLXN) are discussed in this article.
Silexion Therapeutics Corp. (NASDAQ:SLXN), a clinical-stage biotech firm focused on pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, is experiencing significant market momentum. Opening at $2.17, the stock showcased an impressive surge of 51.78%, currently trading at approximately $2.049 with a substantial trading volume of 326.79 million shares. This strong market performance has attracted considerable investor interest, reflecting optimism around Silexion’s potential in the competitive biotech landscape.

In a strategic move to further bolster its financial standing, Silexion has announced definitive agreements for the immediate exercise of outstanding warrants, which are expected to generate around $3.3 million in gross proceeds. This capital injection will be directed towards advancing the company’s innovative oncology initiatives. The agreements specifically involve the exercise of over 2.2 million warrants originally issued in January 2025 at an exercise price of $1.35. In conjunction with these exercises, Silexion will issue new unregistered warrants for the acquisition of an equivalent number of ordinary shares at an exercise price of $1.50, available for immediate exercise with a two-year term.

H.C. Wainwright & Co. serves as the exclusive placement agent for this offering, which is set to close on or about January 30, 2025, pending customary conditions. The company’s product pipeline includes LODER™, which has demonstrated promising results in Phase 2 trials targeting non-resectable pancreatic cancer, alongside SIL-204, a next-generation siRNA candidate aimed at a broader array of KRAS mutations. With a commitment to advancing cancer treatment, Silexion Therapeutics is poised for a transformative impact in the field of oncology.

Related news for (SLXN)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.